Indonesia Pharma and Healthcare Sector Report 2025-2026

Indonesia is one of the ASEAN countries with the fastest-growing pharmaceuticals and healthcare sector. The Indonesian implemented a comprehensive public health insurance programme in 2014 to ensure that all Indonesians have access to healthcare. The gradual implementation of this initiative has allowed more Indonesians to afford healthcare services, incentivising healthcare providers to construct additional capacity to meet the heightened demand. The healthcare system is significantly dependent on imported pharmaceuticals and medical devices as domestic producers cannot manufacture enough of the essential supplies that hospitals and clinics require. To mitigate import dependence, the Indonesian government has recently implemented policies to liberalise the investment environment and encourage foreign companies to establish production facilities in Indonesia.

This report provides a complete and detailed analysis of the "Pharmaceuticals production" sector for Indonesia. EMIS Insights presents in-depth business intelligence in a standard format across countries and regions, providing a balanced mix between analysis and data.

What this report allows you to do:

• Understand the key elements at play in the "Pharmaceuticals production" sector in Indonesia
• Crystallise the forces both driving and restraining this sector in Indonesia
• Ascertain Indonesia’s position in the global sector
• Build a complete perspective on sector trade, investment and employment
• Understand the competitive landscape and who the major players are
• View M&A activity and major deals
• Gain an understanding of the regulatory environment for the sector in Indonesia.
• Build a clear picture of trends, output and consumption for specific sub-sectors